Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

In Brief: Centocor's ReoPro

Executive Summary

Centocor's ReoPro: Phase III study in patients scheduled for angioplasty due to refractory unstable angina will be continued after interim data analysis and recommendation by independent safety and efficacy review committee, Centocor and partner Lilly announce. The CAPTURE (Chimeric 7e3 Antiplatelet in Unstable Angina Refractory to Standard Therapy) trial is being conducted in Europe. The antiplatelet MAb abciximab was approved in the U.S. Dec. 22 for treatment of patients undergoing PTCA who are at high risk for abrupt artery closure...
Advertisement
Advertisement
UsernamePublicRestriction

Register

PS026273

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel